Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers
Conditions
Interventions
AFM24
Atezolizumab 840 MG in 14 ML Injection
Locations
16
United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Independent Public Teaching Hospital #4 in Lublin, Department of Clinical Oncology and Chemotherapy
Lublin, Poland
European Health Center Otwock Fryderyk Chopin Hospital, Department of Clinical Oncology
Otwock, Poland
MED-Polonia, Sp. z o.o. (LLC)
Poznan, Poland
Start Date
November 19, 2021
Primary Completion Date
March 6, 2025
Completion Date
June 11, 2025
Last Updated
August 20, 2025
NCT05720117
NCT06898450
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
Affimed GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions